25+ years of peer-reviewed science on acemannan (VeraCell) and MHE3 — Matured Hop Extract (pHix). Select a category below to explore the research.
Acemannan's neuroprotective activity operates through multiple pathways: macrophage/microglial modulation to reduce neuroinflammation, AKT/mTOR signaling supporting neuronal survival, and antioxidant activity preventing oxidative neuronal damage. Research includes a clinical study in Alzheimer's patients showing direct cognitive and immune improvement.
Acemannan activates macrophages via the mannose receptor (CD206). In the brain, microglia are the equivalent cells — activated microglia clear amyloid plaques (beneficial) or drive neuroinflammation (harmful). Acemannan's immunomodulatory action shifts this balance toward resolution. The AKT/mTOR pathway it activates also governs neuronal protein synthesis and synaptic plasticity — disruption of this same pathway is implicated in Alzheimer's pathology.
An aloe polymannose (acemannan)-centered multinutrient complex significantly improved cognitive function and immune functioning in Alzheimer's disease patients, with measurable improvements in standardized cognition assessments after treatment.
Comprehensive review identifies acemannan as a neuroprotective immunomodulator and antioxidant, with studies showing improved cognitive performance in middle-aged patients with mental fatigue and documented reductions in neuroinflammatory markers.
Systematic review of acemannan-class polysaccharides in neurodegenerative disease shows protective effects through: anti-neuroinflammatory activity, oxidative stress reduction, mitochondrial protection, and modulation of amyloid processing pathways.
In an Alzheimer's disease mouse model, matured hop bitter acids (MHE3, the active compound in pHix) suppressed microglial activation and brain inflammation via the vagus nerve and noradrenergic system, significantly improving memory impairment. Concluded: supplements with hop bitter acids "might be a novel approach for prevention of cognitive decline and dementia."
Human RCT: matured hop bitter acids (MHE3, the active compound in pHix) significantly improved inhibitory attention, selective attention, and mood states in older adults with early cognitive concerns over 6–12 weeks of supplementation.
Acemannan activates the PI3K/AKT/mTOR pathway in cells — the same pathway governing neuronal protein synthesis, synaptic plasticity, and amyloid precursor protein processing. Rapamycin (mTOR inhibitor) completely blocked acemannan's effects, confirming pathway specificity.
Acemannan is classified as a Biological Response Modifier (BRM) — a compound that regulates immune activity bidirectionally rather than simply suppressing or stimulating it. This property is particularly relevant for autoimmune conditions where immune dysregulation drives disease.
Acemannan binds to macrophage mannose receptors (CD206/MRC1), triggering cytokine cascades (TNF-α, IL-1, IL-6, IL-12, IFN-γ). Critically, it also inhibits IL-10 (the primary immunosuppressive cytokine) while promoting IL-2 (T cell growth factor). This balanced regulation of the cytokine environment — rather than crude immune stimulation or blanket suppression — is what distinguishes acemannan as a relevant tool for autoimmune conditions.
A 9-month treatment with 50 mL/day of Aloe barbadensis juice restored euthyroidism (normal thyroid function) in 100% of Hashimoto's hypothyroidism patients. Statistically significant improvements: TSH −61%, free T4 +23%, TPOAb (thyroid antibodies) −56%.
Acemannan's immunomodulatory activity decreases intrathyroid inflammation by regulating cytokine signaling (IL-1β, TNF-α, IFN-γ) and autoantibody production. Acemannan's ROS inhibition prevents oxidative autoimmune damage to thyroid tissue — a primary driver of Hashimoto's progression.
MHBA supplementation directly improved HRV — the gold-standard clinical measure of autonomic nervous system balance and vagal tone. Improved HRV reflects better parasympathetic/sympathetic regulation, directly addressing the autonomic dysregulation central to POTS pathology.
POTS is increasingly recognized as having an autoimmune component (anti-adrenergic receptor antibodies, dysregulated immune signaling). Acemannan's documented regulation of TNF-α, IL-1, IL-6, and IL-10 directly addresses the autoimmune inflammatory pathways implicated in POTS pathogenesis.
Acemannan modulates the cytokine environment elevated in lupus — including TNF-α, IL-1, IL-6 — while promoting regulatory T cell activity via IL-2. Its inhibition of IL-10 (paradoxically elevated in some SLE states) may help re-balance immune homeostasis disrupted in lupus.
Acemannan induces phenotypic maturation of dendritic cells — the primary antigen-presenting cells dysregulated in SLE. Upregulation of MHC Class II, CD40, CD80, CD86, and IL-12 supports recalibration of the adaptive immune dysfunction overactive in lupus.
Review of natural polysaccharides in RA highlights acemannan-class compounds' ability to modulate macrophage polarization in joint synovium — shifting from M1 (pro-inflammatory, joint-destroying) toward M2 (anti-inflammatory, tissue-remodeling) phenotypes. RA synovitis is driven by dysregulated macrophage activity, which acemannan directly targets.
Acemannan demonstrates anti-inflammatory activity by interfering with the arachidonic acid/cyclooxygenase (COX) pathway — the same pathway targeted by NSAIDs commonly used in RA treatment. This COX-inhibitory mechanism is FDA-recognized via the SaliCept acemannan patch.
Acemannan increases macrophage viability and modulates immune signaling via GSK-3β/PI3K/Akt pathways. Alopecia areata results from collapse of hair follicle immune privilege — triggering autoimmune attack. Acemannan's macrophage regulation may help restore this immune privilege and suppress follicular inflammation.
Aloe vera gel (acemannan as primary active compound) reduced scalp inflammation in individuals with alopecia areata by calming the autoimmune response surrounding hair follicles. Reduced perifollicluar inflammation corresponded to decreased shedding and supported regrowth in observed cases.
Evidence from both acemannan and pHix (MHE3) converges on multiple pathways relevant to metabolic and mental health: acemannan addresses gut microbiome optimization, blood glucose stabilization, and systemic inflammation; pHix (MHE3) activates vagal pathways driving thermogenesis, dopamine/norepinephrine modulation, and parasympathetic nervous system restoration.
Acemannan from below: Prebiotic restoration of gut Bifidobacterium → SCFA production → gut-brain signaling → systemic inflammation reduction + blood glucose stabilization.
pHix (MHE3) from above: Bitter taste receptor → CCK → vagus nerve → dopamine/norepinephrine release in hippocampus + BAT thermogenesis activation → visceral fat reduction + mood elevation + HRV improvement.
These are complementary, non-overlapping mechanisms addressing stress and metabolic dysfunction from opposite ends of the gut-brain axis.
200-subject, 12-week, double-blind placebo-controlled RCT: pHix (MHE3) significantly reduced visceral fat area at week 8 (p<0.05) and week 12 (p<0.01), total fat area, and body fat ratio vs. placebo. Zero adverse events. Mechanism: BAT thermogenesis activated via vagal CCK signaling.
Re-analysis of the 2016 RCT data: pHix (MHE3) combined with moderate daily walking produced significantly greater visceral fat reduction than either intervention alone. Even light physical activity synergistically amplifies pHix's thermogenic effect through enhanced fatty acid mobilization from white adipose tissue.
Xanthohumol (pHix's key active compound) cut LDL cholesterol by 80%, reduced insulin levels by 42%, lowered IL-6 inflammatory marker by 78%, and reduced weight gain by 22% vs. controls. Oxygen consumption (metabolic rate) increased significantly.
Randomized double-blind placebo-controlled trial in advanced Type 2 diabetic patients: acemannan significantly lowered fasting blood glucose and glycosylated hemoglobin (HbA1c) with no significant adverse effects on liver or kidney function. The only bioactive compound quantified in the aloe gel tested was acemannan.
Acemannan ameliorates streptozotocin-activated diabetes by attenuating high glucose-induced cellular damage via inhibiting pro-inflammatory cytokines and apoptosis pathways — supporting blood sugar regulation and metabolic stress reduction at the cellular level.
MHBA supplementation improved heart rate variability (HRV) alongside cognitive performance and subjective mood. Elevated HRV is the clinical hallmark of parasympathetic dominance — the physiological state of reduced stress, emotional resilience, and recovery.
First clinical RCT of hop bitter acids in healthy adults: significant improvements in subjective mood state and reduced mental fatigue, attributed to dopamine and norepinephrine modulation via the gut-vagus-hippocampus-prefrontal cortex pathway.
In vitro fermentation with 6 healthy human donors: acemannan significantly increased Bifidobacterium populations and produced butyrate, propionate, and acetate (SCFAs). These are gut-brain signaling molecules: butyrate reduces neuroinflammation, propionate modulates HPA stress axis, and acetate crosses the blood-brain barrier to influence mood-related pathways.
The vagus nerve governs stress response, inflammation, heart rate, digestion, and mood — the primary communication channel between gut and brain. Both acemannan and pHix (MHE3) demonstrate direct vagal activation through distinct, complementary, and well-documented mechanisms.
pHix (MHE3) pathway (direct): MHBA → TAS2R bitter taste receptors in gut enteroendocrine cells → CCK hormone release → CCK receptor on vagal afferents → ascending vagal signal → BAT thermogenesis + hippocampal norepinephrine + HRV improvement. Surgical vagotomy completely abolishes all downstream effects — causal proof.
Acemannan pathway (indirect): Prebiotic → gut Bifidobacterium → butyrate (SCFA) → activation of vagal afferent neurons in the gut wall → cholinergic anti-inflammatory reflex → systemic parasympathetic tone enhancement.
In the mechanistic keystone study, surgically cutting the vagus nerve (subdiaphragmatic vagotomy) completely eliminated MHBA's ability to elevate BAT sympathetic nerve activity and thermogenesis. This constitutes causal proof that vagal activation is the required mechanism — not systemic hormone absorption or direct adipocyte stimulation.
siRNA knockdown experiments confirmed that specific gut bitter taste receptors (TAS2R1, TAS2R8, TAS2R10) are the primary molecular sensors that recognize MHBA and trigger CCK release — the hormonal messenger that activates the vagus nerve. Silencing each receptor significantly suppressed the entire downstream cascade.
Bitter acid receptor activation triggers intracellular calcium (Ca²⁺) flux in enteroendocrine cells, releasing CCK (cholecystokinin). CCK binds CCK receptor 1 (CCKAR) on vagal afferent nerve endings — the precise molecular handoff confirmed between gut bitter sensing and vagal nerve firing.
First direct human measurement of HRV improvement from oral MHBA supplementation. HRV is the clinically validated, non-invasive marker of vagal tone and autonomic nervous system health. Improvements co-occurred with cognitive performance gains, confirming systemic vagal benefit.
MHBA-triggered vagal activation was traced mechanistically to norepinephrine (NE) release in the hippocampus, improving spatial working memory and object recognition. Effect was blocked when the vagus was cut — demonstrating a complete food → gut → vagus → brain → cognition signaling chain.
Acemannan's prebiotic fermentation produces butyrate — a short-chain fatty acid that is a documented activator of vagal afferent neurons in the gut wall through free fatty acid receptor (FFAR3) signaling. This represents acemannan's scientifically grounded indirect pathway to vagal support.
While direct acemannan + ADHD clinical trials have not been published, a growing body of ADHD pathophysiology research identifies gut dysbiosis, neuroinflammation, oxidative stress, and neurotransmitter disruption as core mechanisms — all of which acemannan and pHix (MHE3) directly address through established biological activities.
Landmark research (European Child & Adolescent Psychiatry) found children with ADHD have significantly lower gut microbial diversity, directly affecting dopamine, serotonin, and GABA production — the key neurotransmitters regulating attention and behavior. Acemannan directly addresses this as a prebiotic that measurably increases Bifidobacterium and SCFA production. pHix (MHE3) directly modulates dopamine and norepinephrine signaling via the vagus-hippocampus pathway — the same neurochemical system targeted by ADHD medications.
Acemannan prebiotic fermentation significantly increased Bifidobacterium (major producers of GABA precursors and serotonin-related metabolites) and produced SCFAs. ADHD-specific research confirms these same bacterial populations are consistently reduced in ADHD children, correlating with attention symptom severity.
MHBA improved working memory and attention in cognitive impairment models via norepinephrine release and nicotinic acetylcholine receptor (nAChR) activation — the same neurochemical pathway targeted by ADHD medications (stimulants enhance dopamine/NE; atomoxetine is a selective NE reuptake inhibitor).
Review confirms elevated oxidative stress and neuroinflammation as documented pathological contributors to ADHD. Acemannan's antioxidant activity (ROS scavenging) and anti-inflammatory cytokine modulation (TNF-α, IL-1, IL-6 regulation) directly address these confirmed ADHD mechanisms.
Children with ADHD have significantly lower microbial diversity than neurotypical peers, with reduced Bifidobacterium and Akkermansia directly correlating with impaired dopamine and serotonin synthesis capacity. Acemannan's established prebiotic activity specifically restores the Bifidobacterium populations most depleted in ADHD.
Human RCT: MHBA supplementation improved inhibitory attention (the ability to suppress irrelevant stimuli — a core ADHD deficit) and selective attention over 6–12 weeks. While studied in older adults, these are the same executive function domains impaired in ADHD.
ASD is strongly associated with gut dysbiosis, increased intestinal permeability, immune dysregulation, and neuroinflammation. Acemannan directly addresses each of these documented ASD pathologies through its prebiotic, immunomodulatory, and anti-inflammatory activities. A published paper is explicitly titled "Immune Modulation of Aloe vera: Acemannan and Gut Microbiota Modulator" — both of acemannan's functions are central to ASD pathophysiology.
ASD research consistently identifies three overlapping abnormalities: (1) gut dysbiosis and increased intestinal permeability, (2) immune dysregulation and neuroinflammation, and (3) disrupted gut-brain axis signaling. Acemannan covers all three: as a prebiotic it measurably restores Bifidobacterium and generates SCFAs that repair tight junction proteins (→ gut barrier); its macrophage/dendritic cell modulation recalibrates cytokine balance (→ immune regulation); and its SCFAs activate vagal afferents (→ gut-brain signaling restoration).
Research directly identifies acemannan as both an immune modulator and gut microbiota modulator. ASD is characterized by reduced Bifidobacterium and Bacteroidetes with increased Clostridiales — acemannan's documented prebiotic activity selectively restores the beneficial microbial populations most depleted in ASD.
Nearly 50% of ASD children experience GI symptoms driven by dysbiosis and increased gut permeability. Acemannan-generated butyrate (from prebiotic fermentation) is the primary SCFA that repairs tight junction proteins in the intestinal epithelium — directly reducing the increased gut permeability documented across ASD populations.
Multi-level molecular analysis identifies ASD-associated pro-inflammatory cytokine profiles correlated with gut microbial shifts. Acemannan's documented modulation of TNF-α, IL-1β, IL-6, and regulatory IL-2 directly addresses the cytokine imbalances co-occurring with ASD and correlating with symptom severity.
In vitro fermentation with human microbiota: acemannan significantly increased Bifidobacterium species (specifically reduced in ASD) and produced butyrate, propionate, and acetate. These SCFAs cross the blood-brain barrier and modulate neuroinflammation, neurotransmitter synthesis, and microglial activation in the brain.
Critical finding: orally administered aloe vera gel (acemannan) significantly reduced pathogen growth systemically and enhanced cytotoxic T lymphocyte generation — proving that orally ingested acemannan reaches immune cells systemically, not just locally in the gut. Directly supports its relevance for ASD's systemic immune dysregulation.
Acemannan carries one of the most rigorous natural compound cancer portfolios available: a USDA-approved veterinary cancer treatment (1991, full license 2000), a 2025 molecular docking study confirming tumor burden reduction and apoptotic mechanism, multiple in vitro studies across cancer types, and FDA-recognized use as an oncology adjunct for radiation-induced tissue damage.
Immune-mediated (primary): Acemannan activates macrophages → TNF-α + IL-1 + IFN-γ cytokine triad → direct tumor cytotoxicity. Dendritic cell maturation → CTL (cytotoxic T lymphocyte) activation → targeted tumor killing. IL-10 suppression removes tumor-induced immune evasion.
Direct antiproliferative: Acemannan directly inhibits cancer cell proliferation and induces apoptosis via the caspase cascade (cytochrome c release, Bax/Bcl-2 ratio shift), inhibits NF-κB signaling, and reduces tumor metastasis and cancer stem cell properties. Confirmed by 2025 molecular docking study.
Controlled trial: 8 dogs + 5 cats with histopathologically confirmed fibrosarcomas treated with acemannan immunostimulant + surgery + radiation. 7/13 animals (54%) remained completely tumor-free at study end (440–603+ days). USDA granted full unrestricted biologic license in July 2000 — the highest regulatory tier for a veterinary cancer therapeutic.
Acemannan at 25 and 50 mg/kg orally significantly reduced tumor burden, number, and volume in DMBA-induced mouse skin cancer. Molecular docking confirmed strong binding to NF-κB, Caspase 3, Caspase 9, TNF-α, Bcl-2, and Bax — the key nodes controlling apoptosis and tumor progression. Antioxidant enzyme activities enhanced.
Acemannan fractions (A50 and I50) tested against phthalate-induced colorectal cancer cells significantly inhibited cell viability, metastatic capacity, and cancer stem cell properties. Mechanism: competitive interference with aberrant tumor glycosylation — a known driver of colorectal cancer progression and chemotherapy resistance.
Comprehensive review across the Aloe genus documents three convergent anticancer properties: (1) free radical scavenging preventing oxidative DNA damage, (2) direct antiproliferative inhibition of tumor cell division, (3) immunostimulatory mobilization of host immune defenses against cancer cells.
Acemannan combined with IFN-γ induced apoptosis in macrophage cells via cytochrome c release and Bax translocation — triggering the caspase cascade. This apoptotic mechanism, documented in 1998, was confirmed as acemannan's direct anticancer action in cancer cells by the 2025 molecular docking study.
Acemannan wound dressing gel significantly reduced radiation-induced skin reactions in C3H mice receiving radiation therapy. Mechanism: acemannan-induced TNF and IL-1 regulate tissue repair. FDA recognized this application — acemannan (SaliCept Patch) is used clinically as an oncology adjunct for radiation-induced tissue damage.